Please try another search
Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company’s product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It is developing COYA 101, an autologous regulatory T-cell product candidate that has completed Phase 2a clinical trial for use in the treatment of Amyotrophic Lateral Sclerosis. The company’s product candidates in IND-enabling studies include COYA 301, a low-dose interleukin 2 Treg-enhancing biologic, which is in Phase 2 clinical trial for use in the treatment of Frontotemporal Dementia; and COYA 302, a biologic combination for subcutaneous administration intended to enhance Treg function while depleting T effector function and activated macrophages for use in the treatment of neurodegenerative and autoimmune diseases. It is also developing COYA 201, an antigen directed Treg-derived exosome product candidate that is in preclinical stage for use in the treatment of neurodegenerative, autoimmune, and metabolic diseases; and COYA 206, an antigen directed Treg-derived exosome product candidate, which is in discovery stage. The company has a collaboration with Dr. Reddy's Laboratories SA for the development and commercialization of COYA 302, an investigational combination therapy for treatment of amyotrophic lateral sclerosis. The company was incorporated in 2020 and is headquartered in Houston, Texas.
Name | Age | Since | Title |
---|---|---|---|
Ann L. Lee | 61 | 2021 | Independent Director |
Anabella Villalobos | 63 | 2021 | Independent Director |
Shimon Sakaguchi | - | - | Member of Scientific Advisory Board |
Dov A. Goldstein | 56 | 2021 | Independent Director |
Stanley H. Appel | 90 | - | Member of Scientific Advisory Board |
Howard Berman | 49 | 2020 | Chairman & CEO |
Malcolm K. Brenner | 71 | - | Member of Scientific Advisory Board |
Clive Svendsen | - | - | Member of Scientific Advisory Board |
Hideki Garren | 58 | 2021 | Independent Director |
Lawrence Steinman | 75 | - | Member of Scientific Advisory Board |
Merit E. Cudkowicz | 60 | 2023 | Clinical Advisor |
Guillaume Dorothee | - | 2023 | Member of Scientific Advisory Board |
Dieter Weinand | 64 | 2023 | Independent Director |
Wilbur Louis Ross | 87 | 2023 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review